Most specialty labs treat collection infrastructure as a reactive problem.
Something to address when a draw site exits a critical market. When a Q4 launch underperforms and the post-mortem surfaces coverage as the gap. When an ordering physician calls to ask why their patient's results haven't come back.
The reactive posture is understandable. Collection feels like a background function until it isn't. And the cost of the reactive approach is diffuse enough that it rarely accumulates in a single line item that triggers action.
But the cost is real. And Q4 is where it becomes most visible.
Every specialty lab order that doesn't result in a completed draw is revenue the lab has already invested in — through physician relationship development, test launch spending, marketing, and sales effort — but hasn't collected.
At Q4 ordering volumes, with the seasonal increase in diagnostic monitoring, wellness panels, and year-end insurance benefit utilization, the gap between ordered and realized revenue amplifies. A lab with a 25% collection gap going into Q4 realizes that gap against a higher baseline. The absolute dollar amount of incomplete draws is larger in Q4 than in any other quarter.
The labs that close collection gaps before Q4 begins don't just avoid the problem. They recover revenue from Q4 ordering volume at a higher completion rate — the same orders, more revenue realized.
The ordering physicians who stop routing patients to a lab because of collection access problems rarely make an exit conversation. They simply route the next similar patient to a different lab. The volume declines. The lab's data shows a physician whose order volume has softened. The connection to collection performance is almost never made explicitly.
In Q4, this quiet attrition becomes expensive. The physicians who are routing their highest-value year-end panels — the comprehensive monitoring draws, the specialty diagnostics covered by year-end insurance benefit utilization — are routing them to the labs that have demonstrated reliable completion in their patients' geographies.
For labs with tests in active commercialization, the Q4 commercial data is disproportionately influential. It feeds into year-end performance reviews, payer contracting conversations for 2027, and the commercial planning documents that determine where the lab invests next year.
A test whose Q4 launch data is shaped by a collection completion rate that underrepresents actual ordering physician interest produces misleading signals. The payer conversation that should be about clinical value gets derailed by questions about access. The investment case that should be about market expansion gets undercut by Q4 data that doesn't reflect actual demand.
A lab that closes its primary coverage gaps before Q4 begins recovers revenue from the order volume it already has. This isn't a projection based on new client acquisition or test launches. It's the direct financial return on closing the gap between ordered and completed draws in the markets where the lab currently operates.
For a lab processing 3,000 monthly orders at $140 average value with a 22% completion gap, closing even half of that gap before Q4 recovers $277,200 in Q4 revenue — from orders the lab's commercial team has already generated.
the labs that go into Q4 with collection infrastructure confirmed across their ordering physician networks — not assumed, confirmed — don't spend Q4 managing the consequences of access failures their physicians are experiencing. The physician relationships hold because results arrive. The lab isn't explaining incomplete draws or requesting re-orders. It's receiving the volume Q4 should generate.
A test that goes into Q4 with collection coverage in place produces Q4 data that reflects its actual clinical and commercial performance, not an access-impaired proxy for it. The payer conversations are cleaner. The investor updates are more credible. The 2027 commercial planning is built on data that actually represents what the test can do.
Labs and clients looking to build their collection network on MOMS can be done with relative ease. Connecting with MAPs in areas of need takes just a few clicks of the mouse. MAPs can then undergo Sticklogistics® proficiency modules on the lab's specific collection protocols, and are activated to serve as collection solutions in the target markets.
A lab that starts the process now — in September — is operational at the start of October and Q4. The Q4 volume peak in most specialty test categories runs November through December. There is still time to be operational for the peak, but the window is closing.
A lab that starts in October is operational in late November. Depending on the test category and the markets, that may capture the last portion of Q4 benefit. Or it may mean spending Q4 managing infrastructure that's still being stood up rather than infrastructure that's already working.
The cost of waiting isn't abstract. It's the revenue gap that compounds through Q4, the physician relationships that soften, and the launch data that comes back in January telling a story that's harder to tell than it should have been.
The MAP network coverage page can be found here and shows where active MAPs are located across all 50 states. Labs can view current coverage at any time to understand which markets already have qualified collection professionals available and where new MAP connections would strengthen their Q4 collection position.